First, it was constructed on the basis of the results of a large randomized phase 3 trial, which directly compared IB and BE plus RI as the first-line treatments for patients with untreated CLL aged 65 years or older without the del (17p)/TP53 mutation. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.